Anzeige
Meldung des Tages: 200 % Upside und Rohstoff-Engpass: Entsteht hier der nächste Versorgungs-Gigant?

Neurocrine Biosc. News

Aktie
WKN:  900964 ISIN:  US64125C1099 US-Symbol:  NBIX Branche:  Pharmazeutika Land:  USA
132,30 $
+1,37 $
+1,05%
113,56 € 21:07:34 Uhr
Depot/Watchlist
Marktkapitalisierung *
12,30 Mrd. €
Streubesitz
-
KGV
20,38
Nachhaltigkeits-Score
55 %
Index-Zuordnung
-

Neurocrine Biosciences News

15.05.25 - PR Newswire
Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)
Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal ...
14.05.25 - PR Newswire
Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia
Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal ...
08.05.25 - PR Newswire
Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups
Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing ...
06.05.25 - PR Newswire
Neurocrine Biosciences to Present at Upcoming Investor Conferences in May
Neurocrine Biosciences to Present at Upcoming Investor Conferences in May PR Newswire
06.05.25 - PR Newswire
Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia
Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia PR Newswire
05.05.25 - PR Newswire
Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance
Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance PR Newswire
05.05.25 - PR Newswire
Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia
Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia PR Newswire
30.04.25 - PR Newswire
Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia
Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia PR Newswire
24.04.25 - PR Newswire
Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry
Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive ...
14.04.25 - PR Newswire
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results PR Newswire
04.04.25 - PR Newswire
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer PR Newswire
31.03.25 - PR Newswire
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
Neurocrine Biosciences Presents Real-​World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia PR Newswire
20.03.25 - PR Newswire
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules PR Newswire
17.03.25 - PR Newswire
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules PR Newswire
11.03.25 - PR Newswire
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum PR Newswire
05.03.25 - PR Newswire
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-​Generation VMAT2 Inhibitor, in Healthy Adults PR Newswire
27.02.25 - PR Newswire
Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures
Neurocrine Biosciences Reports Patient-​Reported Outcome Data from KINECT-​PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically ...
25.02.25 - PR Newswire
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March PR Newswire
21.02.25 - PR Newswire
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program PR Newswire
06.02.25 - PR Newswire
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025 PR Newswire

Newssuche

Videos

newspaper
07.04.26 +47,57%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »